Navas-Acosta J, Hernandez-Sanchez A, Gonzalez T, Villaverde Ramiro A, Santos S, Miguel C
Cancers (Basel). 2025; 16(24.
PMID: 39766099
PMC: 11674736.
DOI: 10.3390/cancers16244200.
Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M
Biomark Res. 2024; 12(1):137.
PMID: 39538363
PMC: 11565275.
DOI: 10.1186/s40364-024-00676-9.
Cai J, Fernandez-Hazoury D, Yoshikawa G, Minja A, Huang H, Hwang A
J Hematol. 2024; 13(5):216-223.
PMID: 39493606
PMC: 11526588.
DOI: 10.14740/jh1310.
Nagata Y
Int J Hematol. 2024; 120(4):417-426.
PMID: 39150677
DOI: 10.1007/s12185-024-03824-x.
Rothschild S, Lai G, Tombes R, Clements W
PLoS Genet. 2023; 19(12):e1011102.
PMID: 38117861
PMC: 10766190.
DOI: 10.1371/journal.pgen.1011102.
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Bell H, Blair H, Singh M, Moorman A, Heidenreich O, van Delft F
Cancer Cell Int. 2023; 23(1):202.
PMID: 37715172
PMC: 10502974.
DOI: 10.1186/s12935-023-03057-8.
Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia.
Chitadze G, Stengel A, John-Klaua C, Bruckmuller J, Trautmann H, Kotrova M
Blood. 2022; 141(13):1640-1644.
PMID: 36450137
PMC: 10651768.
DOI: 10.1182/blood.2022017249.
Repeated Lineage Switches in an Elderly Case of Refractory B-Cell Acute Lymphoblastic Leukemia With Gene Amplification: A Case Report and Literature Review.
Takeda R, Yokoyama K, Fukuyama T, Kawamata T, Ito M, Yusa N
Front Oncol. 2022; 12:799982.
PMID: 35402256
PMC: 8983914.
DOI: 10.3389/fonc.2022.799982.
The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations.
Fang Q, Gong X, Liu K, Jia Y, Song Y, Zhang G
Exp Hematol Oncol. 2022; 11(1):22.
PMID: 35395835
PMC: 8991885.
DOI: 10.1186/s40164-022-00274-1.
[Clinical and prognostic values of TP53 mutation in patients with B-lineage acute lymphoblastic leukemia].
Du Y, Lyu K, Xu M, Yao W, Kang H, Han Y
Zhonghua Xue Ye Xue Za Zhi. 2021; 42(5):396-401.
PMID: 34218582
PMC: 8292997.
DOI: 10.3760/cma.j.issn.0253-2727.2021.05.008.
Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT.
Wang Y, Zhou W, Wang J, Karaesmen E, Tang H, McCarthy P
Blood Adv. 2021; 5(1):66-70.
PMID: 33570634
PMC: 7805319.
DOI: 10.1182/bloodadvances.2020003366.
[The effect of TP53 mutations on the clinical outcomes of Ph-negative B-acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation].
Cao X, Zhang Y, Liu D, Zhang J, Wei Z, Xiong M
Zhonghua Xue Ye Xue Za Zhi. 2020; 41(11):908-914.
PMID: 33333693
PMC: 7767807.
DOI: 10.3760/cma.j.issn.0253-2727.2020.11.005.
Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying Molecular Alterations.
Salmoiraghi S, Cavagna R, Guinea Montalvo M, Ubiali G, Tosi M, Peruta B
Genes (Basel). 2020; 11(9).
PMID: 32825230
PMC: 7564830.
DOI: 10.3390/genes11090960.
Capture-based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes.
Cavagna R, Guinea Montalvo M, Tosi M, Paris M, Pavoni C, Intermesoli T
Cancers (Basel). 2020; 12(6).
PMID: 32526928
PMC: 7352935.
DOI: 10.3390/cancers12061505.
The Expression of P53, MDM2, c-myc, and P14 Genes in Newly Diagnosed Acute Lymphoblastic Leukemia Patients.
Farsani M, Rafiee M, Aghaee Nezhad H, Salari S, Gharehbaghian A, Mohammadi M
Indian J Hematol Blood Transfus. 2020; 36(2):277-283.
PMID: 32425378
PMC: 7229094.
DOI: 10.1007/s12288-019-01214-6.
RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.
Sakhdari A, Thakral B, Loghavi S, Kanagal-Shamanna R, Yin C, Zuo Z
Cancer Med. 2019; 9(3):849-858.
PMID: 31804006
PMC: 6997098.
DOI: 10.1002/cam4.2757.
Genetic variants and clinical significance of pediatric acute lymphoblastic leukemia.
Zhang H, Wang H, Qian X, Fan C, Li J, Miao H
Ann Transl Med. 2019; 7(14):296.
PMID: 31475166
PMC: 6694231.
DOI: 10.21037/atm.2019.04.80.
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.
Tirro E, Massimino M, Romano C, Pennisi M, Stella S, Vitale S
Front Oncol. 2019; 9:57.
PMID: 30834235
PMC: 6387953.
DOI: 10.3389/fonc.2019.00057.
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.
Dastur A, Choi A, Costa C, Yin X, Williams A, McClanaghan J
Clin Cancer Res. 2018; 25(1):312-324.
PMID: 30224339
PMC: 6320296.
DOI: 10.1158/1078-0432.CCR-18-0867.
B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy.
Zhang X, Rastogi P, Shah B, Zhang L
Oncotarget. 2017; 8(39):66728-66741.
PMID: 29029550
PMC: 5630450.
DOI: 10.18632/oncotarget.19271.
